Atara Biotherapeutics Research Center in Thousand Oaks. (courtesy photo) Thousand Oaks-based Atara Biotherapeutics is putting the fate of its lead treatment back into the hands of the U.S. Food and Drug Administration after resubmitting its application on July 11. Announced July 15, Atara resubmitted its Biologics License Application to the FDA for tabelecleucel, or Ebvallo.…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
